458 related articles for article (PubMed ID: 29655215)
1. Alteration of serum thymus and activation-regulated chemokine level during biologic therapy for psoriasis: Possibility as a marker reflecting favorable response to anti-interleukin-17A agents.
Shibuya T; Honma M; Iinuma S; Iwasaki T; Takahashi H; Ishida-Yamamoto A
J Dermatol; 2018 Jun; 45(6):710-714. PubMed ID: 29655215
[TBL] [Abstract][Full Text] [Related]
2. Serum fatty acid-binding protein 4 level is inversely correlated with serum thymus and activation-regulated chemokine level in psoriatic patients achieving clear skin by biologics.
Honma M; Shibuya T; Iinuma S; Ishida-Yamamoto A
J Dermatol; 2019 Apr; 46(4):e116-e117. PubMed ID: 30216494
[No Abstract] [Full Text] [Related]
3. Secukinumab for treating plaque psoriasis.
Rothstein B; Gottlieb A
Expert Opin Biol Ther; 2016; 16(1):119-28. PubMed ID: 26577956
[TBL] [Abstract][Full Text] [Related]
4. Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides.
Kakinuma T; Sugaya M; Nakamura K; Kaneko F; Wakugawa M; Matsushima K; Tamaki K
J Am Acad Dermatol; 2003 Jan; 48(1):23-30. PubMed ID: 12522366
[TBL] [Abstract][Full Text] [Related]
5. Safety of biologics in psoriasis.
Kamata M; Tada Y
J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
[TBL] [Abstract][Full Text] [Related]
6. Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity.
Kakinuma T; Nakamura K; Wakugawa M; Mitsui H; Tada Y; Saeki H; Torii H; Asahina A; Onai N; Matsushima K; Tamaki K
J Allergy Clin Immunol; 2001 Mar; 107(3):535-41. PubMed ID: 11240957
[TBL] [Abstract][Full Text] [Related]
7. Serum Thymus and Activation Regulated Chemokine (TARC), IL- 18 and IL-18 Gene Polymorphism as Associative Factors with Atopic Dermatitis.
Gohar MK; Atta AH; Nasr MM; Hussein DN
Egypt J Immunol; 2017 Jun; 24(2):9-22. PubMed ID: 29528575
[TBL] [Abstract][Full Text] [Related]
8. The thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption is a prognostic biomarker of severity of systemic inflammation.
Komatsu-Fujii T; Chinuki Y; Niihara H; Hayashida K; Ohta M; Okazaki R; Kaneko S; Morita E
Allergol Int; 2018 Jan; 67(1):90-95. PubMed ID: 28648978
[TBL] [Abstract][Full Text] [Related]
9. Thymus and activation-regulated chemokine (TARC) in patients with psoriasis: Increased serum TARC levels in patients with generalized pustular psoriasis.
Kawasaki Y; Kamata M; Shimizu T; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
J Dermatol; 2020 Oct; 47(10):1149-1156. PubMed ID: 32677127
[TBL] [Abstract][Full Text] [Related]
10. Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis.
Fitz L; Zhang W; Soderstrom C; Fraser S; Lee J; Quazi A; Wolk R; Mebus CA; Valdez H; Berstein G
Clin Exp Dermatol; 2018 Oct; 43(7):790-797. PubMed ID: 29748971
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab in plaque psoriasis--results of two phase 3 trials.
Langley RG; Elewski BE; Lebwohl M; Reich K; Griffiths CE; Papp K; Puig L; Nakagawa H; Spelman L; Sigurgeirsson B; Rivas E; Tsai TF; Wasel N; Tyring S; Salko T; Hampele I; Notter M; Karpov A; Helou S; Papavassilis C; ;
N Engl J Med; 2014 Jul; 371(4):326-38. PubMed ID: 25007392
[TBL] [Abstract][Full Text] [Related]
12. β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis.
Kolbinger F; Loesche C; Valentin MA; Jiang X; Cheng Y; Jarvis P; Peters T; Calonder C; Bruin G; Polus F; Aigner B; Lee DM; Bodenlenz M; Sinner F; Pieber TR; Patel DD
J Allergy Clin Immunol; 2017 Mar; 139(3):923-932.e8. PubMed ID: 27502297
[TBL] [Abstract][Full Text] [Related]
13. Reduction of serum TARC levels in atopic dermatitis by topical anti-inflammatory treatments.
Yasukochi Y; Nakahara T; Abe T; Kido-Nakahara M; Kohda F; Takeuchi S; Hagihara A; Furue M
Asian Pac J Allergy Immunol; 2014 Sep; 32(3):240-5. PubMed ID: 25268342
[TBL] [Abstract][Full Text] [Related]
14. Association of serum interleukin-18 and other biomarkers with disease severity in adults with atopic dermatitis.
Kou K; Aihara M; Matsunaga T; Chen H; Taguri M; Morita S; Fujita H; Yamaguchi Y; Kambara T; Ikezawa Z
Arch Dermatol Res; 2012 May; 304(4):305-12. PubMed ID: 22146836
[TBL] [Abstract][Full Text] [Related]
15. Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single-center experience.
Momose M; Asahina A; Umezawa Y; Nakagawa H
J Dermatol; 2018 Mar; 45(3):318-321. PubMed ID: 29194723
[TBL] [Abstract][Full Text] [Related]
16. Next-generation biologics in the management of plaque psoriasis: a literature review of IL-17 inhibition.
Yamauchi PS; Bagel J
J Drugs Dermatol; 2015 Mar; 14(3):244-53. PubMed ID: 25738846
[TBL] [Abstract][Full Text] [Related]
17. Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis.
Muramatsu S; Kubo R; Nishida E; Morita A
Mod Rheumatol; 2017 Jan; 27(1):137-141. PubMed ID: 27194220
[TBL] [Abstract][Full Text] [Related]
18. Chemokine expression in diverse nonimmediate drug hypersensitivity reactions: focus on thymus activation-regulated chemokine, cutaneous T-cell-attracting chemokine, and interleukin-10.
Wang F; He D; Tang X; Zhang X
Ann Allergy Asthma Immunol; 2014 Aug; 113(2):204-8. PubMed ID: 24932689
[TBL] [Abstract][Full Text] [Related]
19. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
Al-Mutairi N; Nour T
Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
[TBL] [Abstract][Full Text] [Related]
20. Serum measurement of thymus and activation-regulated chemokine/CCL17 in children with atopic dermatitis: elevated normal levels in infancy and age-specific analysis in atopic dermatitis.
Fujisawa T; Nagao M; Hiraguchi Y; Katsumata H; Nishimori H; Iguchi K; Kato Y; Higashiura M; Ogawauchi I; Tamaki K
Pediatr Allergy Immunol; 2009 Nov; 20(7):633-41. PubMed ID: 19236603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
